ARID1A and gastric cancer: A similar in vitro study also confirmed that in ARID1A-deficient GC cells, the PI3K/AKT pathway was activated, which induced the proliferation of GC cells, and ARID1A-deficient GC cells were more sensitive to PI3K and AKT inhibitors [61].